[go: up one dir, main page]

NO975437D0 - Nytt CD40L-mutein - Google Patents

Nytt CD40L-mutein

Info

Publication number
NO975437D0
NO975437D0 NO975437A NO975437A NO975437D0 NO 975437 D0 NO975437 D0 NO 975437D0 NO 975437 A NO975437 A NO 975437A NO 975437 A NO975437 A NO 975437A NO 975437 D0 NO975437 D0 NO 975437D0
Authority
NO
Norway
Prior art keywords
new
cd40l
mutein
cd40l mutein
muteins
Prior art date
Application number
NO975437A
Other languages
English (en)
Other versions
NO317735B1 (no
NO975437L (no
Inventor
Richard J Armitage
Iii William C Fanslow
Melanie K Spriggs
Subhashini Srinivasan
Marylou G Gibson
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/477,733 external-priority patent/US5981724A/en
Priority claimed from US08/484,624 external-priority patent/US5962406A/en
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of NO975437D0 publication Critical patent/NO975437D0/no
Publication of NO975437L publication Critical patent/NO975437L/no
Publication of NO317735B1 publication Critical patent/NO317735B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14Fungi; Culture media therefor
    • C12N1/16Yeasts; Culture media therefor
    • C12N1/18Baker's yeast; Brewer's yeast
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/32Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Botany (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Amplifiers (AREA)
  • Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Reverberation, Karaoke And Other Acoustics (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO19975437A 1995-06-07 1997-11-26 Isolert DNA som koder for CD40L-mutein, fremgangsmate for fremstilling av dette, rekombinant ekspresjonsvektor, vertscelle, samt CD40L-polypeptid. NO317735B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/477,733 US5981724A (en) 1991-10-25 1995-06-07 DNA encoding CD40 ligand, a cytokine that binds CD40
US08/484,624 US5962406A (en) 1991-10-25 1995-06-07 Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
PCT/US1996/009632 WO1996040918A2 (en) 1995-06-07 1996-06-06 Novel cd40l mutein

Publications (3)

Publication Number Publication Date
NO975437D0 true NO975437D0 (no) 1997-11-26
NO975437L NO975437L (no) 1998-02-06
NO317735B1 NO317735B1 (no) 2004-12-13

Family

ID=27045653

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19975437A NO317735B1 (no) 1995-06-07 1997-11-26 Isolert DNA som koder for CD40L-mutein, fremgangsmate for fremstilling av dette, rekombinant ekspresjonsvektor, vertscelle, samt CD40L-polypeptid.

Country Status (15)

Country Link
EP (1) EP0832229B1 (no)
JP (1) JP3279573B2 (no)
KR (1) KR100453314B1 (no)
AT (1) ATE257858T1 (no)
AU (1) AU693713B2 (no)
CA (1) CA2222914C (no)
DE (1) DE69631331T2 (no)
DK (1) DK0832229T3 (no)
ES (1) ES2214541T3 (no)
IL (1) IL122174A (no)
MX (1) MX9709447A (no)
NO (1) NO317735B1 (no)
NZ (1) NZ311335A (no)
PT (1) PT832229E (no)
WO (1) WO1996040918A2 (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
CA2259140C (en) * 1996-07-10 2008-09-30 Immunex Corporation Method of activating dendritic cells
DE122010000048I1 (de) 1996-12-23 2011-05-05 Immunex Corp Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
CA2328140C (en) 1998-05-14 2012-03-13 Immunex Corporation Method of inhibiting osteoclast activity
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
US20040053249A1 (en) * 2000-05-26 2004-03-18 Junko Tohma Fas ligand-fused proteins
PT2087908T (pt) 2001-06-26 2018-07-16 Amgen Inc Anticorpos contra opgl
DK1434871T3 (en) 2001-09-20 2017-04-18 Immunex Corp SELECTION OF CELLS EXPRESSING HETEROMERIC POLYPEPTIDES
DK1594955T3 (da) 2003-02-14 2012-06-25 Biogen Idec Inc Ekspressionskassette og vektor til transient eller stabil ekspression af eksogene molekyler
JP3936673B2 (ja) * 2003-06-02 2007-06-27 国立大学法人群馬大学 Cd47部分ペプチドと抗shps−1モノクロナール抗体
WO2005035570A2 (en) * 2003-10-10 2005-04-21 Xencor, Inc. Variants of cd40l protein
CA2584211C (en) 2004-10-22 2014-07-08 Amgen Inc. Methods for refolding of recombinant antibodies
AU2007294731B2 (en) 2006-09-13 2014-04-17 Abbvie Inc. Cell culture improvements
EP2500416A1 (en) 2006-09-13 2012-09-19 Abbott Laboratories Cell culture improvements
EP2066339B1 (en) 2006-09-18 2014-08-13 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses
EP2172550B1 (en) 2007-06-29 2014-08-06 Daiichi Sankyo Company, Limited C-TERMINAL-alpha-AMIDATED RECOMBINANT ENZYME DERIVATIVE
EP3418299B1 (en) 2007-09-14 2024-11-13 Amgen Inc. Homogeneous antibody populations
NZ585776A (en) 2007-10-30 2012-07-27 Univ Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
WO2009059298A2 (en) 2007-11-01 2009-05-07 Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancinc immune responses to eimeria
US8187836B2 (en) 2008-01-15 2012-05-29 Abbott Laboratories Mammalian expression vectors and uses thereof
NO2501822T3 (no) 2009-11-17 2018-01-13
CN102811734B (zh) 2010-01-21 2016-02-10 阿肯色大学评议会 增强免疫应答的疫苗载体和方法
ES2753142T3 (es) 2010-06-09 2020-04-07 Univ Arkansas Vacuna y métodos para reducir una infección por Campylobacter
ES2968398T3 (es) 2013-02-14 2024-05-09 Univ Arkansas Composiciones y métodos para potenciar las respuestas inmunitarias a Eimeria o limitar la infección por Eimeria
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
EP3578190A1 (en) 2013-03-15 2019-12-11 The Board of Trustees of the University of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
JP7049988B2 (ja) 2015-08-05 2022-04-07 ヤンセン バイオテツク,インコーポレーテツド 抗cd154抗体及びこれを使用する方法
WO2017083604A1 (en) 2015-11-12 2017-05-18 Amgen Inc. Triazine mediated pharmacokinetic enhancement of therapeutics
TWI843057B (zh) 2016-05-03 2024-05-21 阿肯色州大學董事會 包含免疫刺激性及抗原性多肽的酵母菌疫苗載體以及其使用方法
EA201892588A1 (ru) 2016-05-11 2019-06-28 Амген Инк. Прямой отбор клеток, экспрессирующих высокие уровни гетеромерных белков, с использованием глутаминсинтетазных векторов внутригенной комплементации
AR108468A1 (es) * 2016-05-13 2018-08-22 Medimmune Llc POLIPÉPTIDOS DE FUSIÓN CD40L-Fc Y MÉTODOS DE USO DE LOS MISMOS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69233402T3 (de) * 1991-10-25 2009-06-25 Immunex Corp., Seattle Neue cytokine
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
CA2146559A1 (en) * 1992-10-23 1994-05-11 Melanie K. Spriggs Methods of preparing soluble, oligomeric proteins

Also Published As

Publication number Publication date
IL122174A0 (en) 1998-04-05
EP0832229A2 (en) 1998-04-01
MX9709447A (es) 1998-02-28
NZ311335A (en) 1998-05-27
NO317735B1 (no) 2004-12-13
DE69631331T2 (de) 2004-11-18
NO975437L (no) 1998-02-06
PT832229E (pt) 2004-06-30
KR19990022141A (ko) 1999-03-25
JP3279573B2 (ja) 2002-04-30
DK0832229T3 (da) 2004-05-03
JPH11504819A (ja) 1999-05-11
EP0832229B1 (en) 2004-01-14
KR100453314B1 (ko) 2004-12-17
WO1996040918A2 (en) 1996-12-19
AU693713B2 (en) 1998-07-02
IL122174A (en) 2004-07-25
ES2214541T3 (es) 2004-09-16
WO1996040918A3 (en) 1997-01-23
DE69631331D1 (de) 2004-02-19
AU6263896A (en) 1996-12-30
CA2222914C (en) 2002-04-02
ATE257858T1 (de) 2004-01-15
CA2222914A1 (en) 1996-12-19

Similar Documents

Publication Publication Date Title
NO975437L (no) Nytt CD40L-mutein
DK0772624T3 (da) Interleukin-15
ATE353906T1 (de) Cd27 ligand
FI956075A0 (fi) Rekombinantti, ihon sarveiskerroksen kymotyptinen entsyymi (SCCE)
IL96907A0 (en) Proteins produced by human lymphocytes,a dna sequence coding for said proteins and their pharmaceutical and biological application
ATE221125T1 (de) Klonierte glutaminsäure-decarboxylase
EE05111B1 (et) Interferoon-beetaga sulandatud valgud ja nende kasutamine
DE69737978D1 (de) Als 2f1 bezeichnetes rezeptorprotein
BR9607583B1 (pt) plasmìdios procarióticos recombinantes.
FR2686620B1 (fr) Serum-albumine humaine, preparation et utilisation.
DE59410132D1 (de) Humanes zirkulierendes cytokin cc-1
AU3162097A (en) Retinoid metabolizing protein
SE9600742D0 (sv) Vridbart arrangemang
BR9407357A (pt) Novos tripeptideos utilizáveis em terapia cns e imune
DK0946591T3 (da) Klonede glucagon-lignende peptid-2 receptorer
MX9205978A (es) Nuevas proteinas inhibidoras de trombina de garrapatas.
AU3928193A (en) Plasmilar gene, peptide and methods of use
FI902700A0 (fi) Vaevnadplasminogenaktivatorderivat.
AU6981794A (en) Protein which catalyses peptide refolding and uses thereof
SE9302168D0 (sv) Ryggsaeck med ihopfaellbar sittstol
MX9700213A (es) Citocina novedosa designada como lerk-5.